If you think this trial is relevant to your situation, please contact your Cancer Specialist to discuss further.
RoLaCaRT-1: Robotic versus Laparoscopic Colon – a Randomized Trial
Purpose of the Study
Removal of the tumour is the most important treatment for colon cancer, giving the best likely health outcome and allowing treatment options that are available following surgery. RoLaCaRT-1 compares the use of robotic surgery with laparoscopic surgery for the surgical treatment of right-sided colon cancer, the study will aim to determine whether the newer robotic technology will allow greater operative advantages which translate to improved rates of “successful surgery” and better patient-oriented clinical outcomes.
DETAILED INFORMATION AVAILABLE
More detailed information to come.
Associate Professor Andrew Stevenson
If you think this clinical trial may be relevant to your patient or to discuss further, please contact the Clinical Trial team.
RoLaCaRT: Robotic versus Laparoscopic Colon – a Randomized Trial
The introduction of new surgical procedures, techniques and technology are often associated with significant increases in health cost both from the capital investment and disposables used per case. There has been a steady increase in the uptake of robotics in colorectal surgery in recent years. This may have important implications in terms of overall impact on healthcare costs to governments, private insurers and to patients. This study aims to determine whether the newer robotic technology will allow greater operative advantages which translate to improved rates of “successful surgery” and better patient-oriented clinical outcomes.
The aim of this study is to evaluate the clinical outcomes from performing right hemicolectomies robotically compared with routine laparoscopic colectomy in patients with adenocarcinoma (tumour or malignant polyp) of the caecum, ascending or proximal transverse colon.
Key Eligibility Criteria
1. Adults, aged 18 years and older, adenocarcinoma (tumour or malignant polyp) of the caecum, ascending or proximal transverse colon. Disease must be confirmed by histological, radiological, endoscopic diagnosis
AGITG Working Party, New Concept, Lay Summary Page 3 of 4
2. ECOG performance status 0-2
3. Willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments
4. Life expectancy of at least 12 weeks
5. Surgery to be performed within 40 days of randomisation
6. Signed, written informed consent
1. Evidence of T4 disease invading adjacent organs.
2. History of conditions that would preclude use of a minimally-invasive approach (e.g. multiple previous major laparotomies, severe adhesions).
3. Concurrent or previous invasive hepatic or duodenal malignancy within five years prior to registration.
4. Specific comorbidities or conditions (e.g. psychiatric) or concomitant medications which may increase risk of morbidity
5. Other co-morbidities or conditions that may compromise assessment of key outcomes
6. Participation in any investigational drug study within the previous 4 weeks
7. Evidence of systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude surgery, or other severe incapacitating disease, i.e. ASA IV (a patient with severe systemic disease that is a constant threat to life) or ASA V (a moribund patient who is not expected to survive without the operation).
8. Pregnancy or lactation. Women must be post-menopausal, infertile, or use a reliable means of contraception. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to registration.